Clinical Trial Update: A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ranibizumab for choroidal neovascularization secondary to age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Choroidal Neovascularization

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Choroidal Neovascularization, Age-related Macular Degeneration | Phase 3 | Status: COMPLETED